Differential stimulation of murine resident peritoneal cells by selectively opsonized encapsulated and acapsular Cryptococcus neoformans.
about
Virulence factors of medically important fungiCryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans.Opsonic requirements for dendritic cell-mediated responses to Cryptococcus neoformans.Pulmonary infection with an interferon-gamma-producing Cryptococcus neoformans strain results in classical macrophage activation and protection.Characterization of cellular infiltrates and cytokine production during the expression phase of the anticryptococcal delayed-type hypersensitivity response.Effect of endothelial cells on phagocyte-mediated anticryptococcal activityEffect of mannose-binding protein on binding of Cryptococcus neoformans to human phagocytes.Antigen-induced protective and nonprotective cell-mediated immune components against Cryptococcus neoformansPhenotypic and functional characterization of human lymphocytes activated by interleukin-2 to directly inhibit growth of Cryptococcus neoformans in vitroCyclic AMP-dependent protein kinase controls virulence of the fungal pathogen Cryptococcus neoformansThe capsule of Cryptococcus neoformans reduces T-lymphocyte proliferation by reducing phagocytosis, which can be restored with anticapsular antibodySusceptibilities of Cryptococcus neoformans strains to platelet binding in vivo and to the fungicidal activity of thrombin-induced platelet microbicidal proteins in vitro.Inhibition of Cryptococcus neoformans replication by nitrogen oxides supports the role of these molecules as effectors of macrophage-mediated cytostasisBinding of Cryptococcus neoformans by human cultured macrophages. Requirements for multiple complement receptors and actin.Interleukin-17 is not required for classical macrophage activation in a pulmonary mouse model of Cryptococcus neoformans infection.Regulation of cytokine production during the expression phase of the anticryptococcal delayed-type hypersensitivity response.Anticryptococcal resistance in the mouse brain: beneficial effects of local administration of heat-inactivated yeast cells.Pathogenesis of Cryptococcus neoformans in congenitally immunodeficient beige athymic miceActivation and binding of opsonic fragments of C3 on encapsulated Cryptococcus neoformans by using an alternative complement pathway reconstituted from six isolated proteins.Role of tumor necrosis factor and gamma interferon in acquired resistance to Cryptococcus neoformans in the central nervous system of mice.Downregulation by cryptococcal polysaccharide of tumor necrosis factor alpha and interleukin-1 beta secretion from human monocytesgamma Interferon gene expression and release in human lymphocytes directly activated by Cryptococcus neoformans and Candida albicansProtection against cryptococcosis by using a murine gamma interferon-producing Cryptococcus neoformans strain.Direct activity of human T lymphocytes and natural killer cells against Cryptococcus neoformans.Role of phagocytosis in the virulence of Cryptococcus neoformans.Molecular characterization of the humoral responses to Cryptococcus neoformans infection and glucuronoxylomannan-tetanus toxoid conjugate immunization.Experimental model of intracerebral infection with Cryptococcus neoformans: roles of phagocytes and opsonization.Killing of Cryptococcus neoformans strains by human neutrophils and monocytes.A monoclonal antibody to gamma interferon blocks augmentation of natural killer cell activity induced during systemic cryptococcosisInhibition of intracellular growth of Histoplasma capsulatum yeast cells by cytokine-activated human monocytes and macrophages.Protective murine monoclonal antibodies to Cryptococcus neoformansGrowth inhibition of Cryptococcus neoformans by cultured human monocytes: role of the capsule, opsonins, the culture surface, and cytokines.Activation of human peripheral blood mononuclear cells by interleukin-2 and granulocyte-macrophage colony-stimulating factor to inhibit Cryptococcus neoformans.A proteomic-based approach for the identification of immunodominant Cryptococcus neoformans proteins.Identification and characterization of Cryptococcus neoformans protein fractions that induce protective immune responsesCryptococcus neoformans fails to induce nitric oxide synthase in primed murine macrophage-like cells.Pronounced enhancement of .NO-dependent antimicrobial action by an .NO-oxidizing agent, imidazolineoxyl N-oxide.Cytokine treatment of central nervous system infection: efficacy of interleukin-12 alone and synergy with conventional antifungal therapy in experimental cryptococcosis.Effect of in vivo macrophage colony-stimulating factor on fungistasis of bronchoalveolar and peritoneal macrophages against Cryptococcus neoformans.Occurrences, immunoglobulin classes, and biological activities of antibodies in normal human serum that are reactive with Cryptococcus neoformans glucuronoxylomannan.
P2860
Q24683790-EAF7D2E5-5B0E-4372-B60B-6E25FD4E0EA7Q30424017-1767687F-DD85-4BFF-B2C4-45F76C927C8DQ33559279-14BEB78A-C708-44BB-803C-18FFE7FE60F8Q33597147-0B4BDC4F-9A21-4D54-A2A8-2D5629FE292CQ33602419-1BA012C4-8C1F-4FF3-830F-D1C057E2C4F9Q33608093-056E492D-A132-44A7-95AF-EB1229233AE0Q33615018-2C1AB8AC-4AF5-4435-B1DE-53D6F1147809Q33754495-C4DD5DC8-AE26-406F-B688-4F846C49551EQ33895762-DD406FBE-D45E-4F6A-A6A7-FEEA46347E9BQ33968048-B4F40445-73EB-4C5E-AF91-042F1FC94F0DQ34001769-BA5E2976-8BB3-4730-9183-BEC778BCC3F5Q34006152-D952ADAB-DFF0-4429-A3E5-D83CF2CE88A1Q34117500-2413B090-3420-4B25-A2BC-7ABDF7430AD5Q34236760-A2402714-1677-41B0-A2F0-A1402983CF2AQ34309693-44C01AC3-4959-4C96-BA46-0E10DB825203Q34530361-EB4B54FC-3ADE-4783-B95D-9D235EE1A9F9Q34532590-7EDF0853-1B0D-477B-A43A-51C760C4528BQ35105915-CE7820B3-4110-46B0-89BD-659C4CEB36D9Q35110746-E69AC77A-0009-4CC3-A2AE-3734F21DA968Q35408288-C4DBA4D3-2288-45B8-A5DD-7807F569554BQ35427625-85C39045-95FD-4152-9D47-1096CC211FC0Q35488223-66300BA8-82F5-45FD-B899-94CBB1623207Q35689384-CB8B5906-6127-431C-98D4-00FF132B5E57Q35771518-561CCB9F-E2C4-4C7D-B6D1-C9EBD44620E8Q35911335-C6B7F592-9B5B-4B65-A624-313A17635890Q36361541-4030A691-0E07-452E-87EF-2FB42E570C24Q36950530-5F23140B-6A11-49A3-9476-781D58E1E8B1Q36958548-4EE94447-9B80-4FFC-8873-A08D78E4BC28Q36960843-FB8719E6-3E35-49CC-A26C-4CDD80DB04A0Q36961867-D8703708-A815-4073-99CE-00097012A914Q36969771-1947D1B0-7FA8-49FE-AB79-D4D557BFC96EQ36980669-3007B6E6-45D0-40F2-94CC-3D75061720CDQ36987563-6EDC21B6-086E-46A4-B3FF-AC0F4BA7F358Q37367575-E811BFB7-8B49-4300-8CC8-5B825B65F526Q37562226-6F75CA42-0AE7-4ECF-A210-41898249B12BQ39821669-67711B13-2B3B-4B6B-A1A3-1670BC8EA773Q40268392-4EB864F6-75F2-4DE9-9F36-552622B04185Q40285200-E7B7AF7D-80EC-447D-9EF2-228CCB945A8FQ40286418-31F8727E-845F-4C6D-8230-FEC7046C77E4Q40374574-7EBDF95E-2EC1-4E86-9C18-D5A5C5F7AEB1
P2860
Differential stimulation of murine resident peritoneal cells by selectively opsonized encapsulated and acapsular Cryptococcus neoformans.
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
1988年论文
@zh
1988年论文
@zh-cn
name
Differential stimulation of mu ...... sular Cryptococcus neoformans.
@en
type
label
Differential stimulation of mu ...... sular Cryptococcus neoformans.
@en
prefLabel
Differential stimulation of mu ...... sular Cryptococcus neoformans.
@en
P2860
P1476
Differential stimulation of mu ...... sular Cryptococcus neoformans.
@en
P2093
D J DiBenedetto
S M Levitz
P2860
P304
P407
P577
1988-10-01T00:00:00Z